Figure 2.
Plasma concentration–time profile of (A) sacubitril, (B) sacubitrilat and (C) valsartan following administration of 200 mg twice‐daily sacubitril/valsartan with or without furosemide (pharmacokinetic analysis set)
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.